Ol'binskaia L I, Morozova T E
Ter Arkh. 1987;59(4):103-6.
The results of clinicoinstrumental investigations in 33 patients with coronary heart disease and coronary heart disease combined with essential hypertension complicated by stage I-II cardiac insufficiency showed that therapy with captopril at a daily dose of 25-75 mg resulted in the correction of cardiac insufficiency in 84% of the patients, with a hypotensive effect in 80%. Captopril improved myocardial contractility, decreased pressure in the pulmonary artery and total peripheral vascular resistance and produced no major side-effects.
对33例冠心病患者以及冠心病合并原发性高血压并伴有I-II期心脏功能不全的患者进行临床器械检查的结果显示,每日服用剂量为25 - 75毫克的卡托普利进行治疗,84%的患者心脏功能不全得到纠正,80%的患者有降压效果。卡托普利改善了心肌收缩力,降低了肺动脉压力和总外周血管阻力,且未产生重大副作用。